CDEK
← All drugs Report issue

cisatracurium

Trade name: nimbex

Small moleculeapproved

Approved

Dec 15, 1995

Cisatracurium is a cis-cis isomer of atracurium and five time as potent as atracurium. The drug is approved by FDA and marketed under the name Nimbex. It is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation due to its antagonistic properties toward nicotinic acetylcholine receptors. — NCATS

Clinical trial activity

64 trials · 69 clinical orgs · 24 marketing orgs

Phase 1
2
Phase 2
7
Phase 3
5
Phase 4
24

Earliest trial started Mar 1, 2006 (NCT00299650)

Timeline

1990s

  1. Dec 15, 1995

    AbbVie — Earliest FDA Approval

  2. Dec 15, 1995

    AbbVie — NDA Secondary Org

  3. Dec 15, 1995

    AbbVie — NDA Organization

2000s

  1. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Feb 3, 2012

    Sandoz — Marketing Organization

  2. Feb 3, 2012

    Novartis — Marketing Organization

  3. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

  4. Feb 26, 2015

    Fresenius — Marketing Organization

  5. Jan 27, 2017

    Hengrui Therapeutics, Inc. — Marketing Organization

  6. Jan 27, 2017

    Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. — Marketing Organization

  7. Jun 16, 2017

    Accord Research — Marketing Organization

  8. Mar 30, 2018

    Hospira — Marketing Organization

  9. Mar 30, 2018

    Pfizer — Marketing Organization

  10. Feb 20, 2019

    Somerset Pharmaceuticals — Marketing Organization

  11. Feb 20, 2019

    Mylan — Marketing Organization

  12. Apr 24, 2019

    ANDA Repository — Marketing Organization

  13. Apr 25, 2019

    Nanjing King-Friend — Marketing Organization

  14. Apr 25, 2019

    Meitheal — Marketing Organization

  15. Nov 4, 2019

    Zydus Discovery DMCC — Marketing Organization

2020s

  1. May 4, 2020

    Piramal — Marketing Organization

  2. May 8, 2020

    Aurobindo Pharma — Marketing Organization

  3. May 8, 2020

    Eugia Pharma — Marketing Organization

  4. Nov 6, 2020

    Sagent Pharmaceuticals, Inc. — Marketing Organization

  5. Nov 6, 2020

    Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization

  6. May 24, 2022

    Gland Pharma Ltd — Marketing Organization

  7. Jun 28, 2022

    Hikma — Marketing Organization

  8. Jun 9, 2023

    Caplin Point Laboratories — Marketing Organization

  9. Jan 1, 2024

    Earliest Phase 1 Sponsor(trial)

  10. Mar 8, 2024

    Hainan Poly Pharm — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedDec 15, 1995

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC
Mol. weight
929.16 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • (1r,1'r,2r,2'r)-atracurium besylate
  • (1r,1'r,2r,2'r)-atracurium besylate
  • (1r-cis,1'r-cis)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate
  • (1r-cis,1'r-cis)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate
  • (1r-cis,1'r-cis)-atracurium besylate
  • (1r-cis,1'r-cis)-atracurium besylate
  • 51w89
  • 51 w89
  • 51 w89
  • besilate de cisatracurium
  • besilate de cisatracurium
  • besilato de cisatracurio
  • besilato de cisatracurio
  • cisastracurium
  • cisastracurium besylate
  • cisatracurii besilas
  • cisatracurii besilas
  • cisatracurium
  • cisatracurium
  • cisatracurium
  • cisatracurium
  • cisatracurium
  • cisatracurium
  • cisatracurium
  • cisatracurium
  • cis-atracurium
  • cisatracurium besilate
  • cisatracurium besilate
  • cisatracurium besilate
  • cisatracurium besilate
  • cisatracurium besilate
  • cisatracurium besilate
  • cisatracurium besylate
  • cisatracurium besylate
  • cisatracurium besylate
  • cisatracurium besylate
  • cisatracurium besylate
  • cisatracurium besylate
  • cisatracurium besylate
  • cisatracurium dibenzenesulfonate
  • cisatracurium dibenzenesulfonate
  • cisatracurium-kation
  • cisatracurium-kation
  • nimbex
  • nimbex
  • nimbex
  • nimbex
  • nimbex
  • victracurium

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07211399Early Phase 1 (Phase 1)Jan 1, 2026University of Pittsburgh
NCT07203287Phase 4Aug 26, 2025University of Texas, Galveston
NCT07143799N/AAug 11, 2025Sohag University
NCT07185074Phase 4Jan 17, 2025Shanghai University of Traditional Chinese Medicine
NCT06561672Early Phase 1 (Phase 1)Sep 1, 2024Zagazig University
NCT06514209N/AJun 28, 2024Southeast University
NCT06343753N/AMay 1, 2024Ain Shams University
NCT06203405N/ADec 22, 2023Siriraj Hospital
NCT06214169N/AJun 15, 2023Watim Medical
NCT05736744Phase 2/Phase 3 (Phase 3)Mar 20, 2023Assiut University
NCT05760976N/AFeb 1, 2023Yangzhou University
NCT05752799N/AJan 1, 2023Aristotle University of Thessaloniki, Gennimatas Hospital, Athens
NCT05624424Phase 4Nov 15, 2022Nanchang University, Yichang Humanwell Pharmaceutical Co.,Ltd
NCT05527314N/AOct 1, 2022Nanchang University
NCT05172531N/AAug 29, 2022Tianjin University of Traditional Chinese Medicine
NCT05310110N/AApr 12, 2022Chang Gung University
NCT06714981N/AJan 2, 2022Medical University of Lodz
NCT05153525Phase 4Dec 20, 2021Tanta University
NCT05146232N/ADec 1, 2021Tanta University
NCT04524585N/AOct 1, 2020University of Toronto
Showing 20 of 64 trials
Page 1 / 4

Organizations

Research & Development (69)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Jiao Tong UniversityAcademic/Hospital7612012
People's Liberation Army of ChinaGovernment3222012
Ain Shams UniversityAcademic/Hospital2212018
Aix-University of MarseilleAcademic/Hospital2212006
Chinese Medical AssociationAcademic/Hospital2012014
Fudan UniversityAcademic/Hospital2122012
Nanchang UniversityAcademic/Hospital2222022
National Taiwan UniversityAcademic/Hospital2212015
Peking UniversityAcademic/Hospital2222012
Shaanxi Provincial People's HospitalAcademic/Hospital2212014
Southern Medical UniversityAcademic/Hospital2112012
Tanta UniversityAcademic/Hospital2222021
Tianjin Medical UniversityAcademic/Hospital2022012
University of Sao PauloAcademic/Hospital2222015
Yangzhou No.1 People's HospitalAcademic/Hospital2112013
Yangzhou UniversityAcademic/Hospital2222015
Aristotle University of ThessalonikiAcademic/Hospital1012023
Assiut UniversityAcademic/Hospital1112023
Autonomous University of MadridAcademic/Hospital1112013
Central South UniversityAcademic/Hospital1012012
69 organizations
Page 1 / 4

Marketing (30)

OrganizationOrg typeRelationshipDate
ANDA RepositoryFor profitMKTGApr 24, 2019
AbbVieFor profitNDA2Dec 15, 1995
AbbVieFor profitNDADec 15, 1995
Accord ResearchFor profitMKTGJun 16, 2017
Aurobindo PharmaFor profitMKTGMay 8, 2020
Caplin Point LaboratoriesFor profitMKTGJun 9, 2023
Eugia PharmaFor profitMKTGMay 8, 2020
FreseniusFor profitMKTGFeb 26, 2015
Gland Pharma LtdFor profitMKTGMay 24, 2022
Hainan Poly PharmFor profitMKTGMar 8, 2024
Hengrui Therapeutics, Inc.For profitMKTGJan 27, 2017
Hengrui Therapeutics, Inc.For profitSYNJan 27, 2017
HikmaFor profitMKTGJun 28, 2022
HospiraFor profitMKTGMar 30, 2018
HospiraFor profitSYNMar 30, 2018
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.For profitMKTGJan 27, 2017
MeithealFor profitMKTGApr 25, 2019
MylanFor profitMKTGFeb 20, 2019
Nanjing King-FriendFor profitMKTGApr 25, 2019
Nichi-Iko Pharmaceutical Co., Ltd.For profitMKTGNov 6, 2020
NovartisFor profitMKTGFeb 3, 2012
PfizerFor profitMKTGMar 30, 2018
PiramalFor profitMKTGMay 4, 2020
PiramalFor profitSYNMar 11, 2022
PiramalFor profitSYNMay 24, 2022
Sagent Pharmaceuticals, Inc.For profitMKTGNov 6, 2020
SandozFor profitMKTGFeb 3, 2012
Somerset PharmaceuticalsFor profitSYNApr 24, 2019
Somerset PharmaceuticalsFor profitMKTGFeb 20, 2019
Zydus Discovery DMCCFor profitMKTGNov 4, 2019